Literature DB >> 19449332

Genetic variation in neuregulin1 is associated with differences in prefrontal engagement in children.

Andrea Mechelli1, Essi Viding, William Pettersson-Yeo, Stefania Tognin, Philip K McGuire.   

Abstract

The majority of psychopathology is rooted early in life and first emerges during childhood and adolescence. However, little is known about how risk genes affect brain function to increase biological vulnerability to psychopathology in childhood, because most imaging genetic studies published so far have been conducted on adult participants. We examined the impact of neuregulin1 (NRG1), a probable susceptibility gene for schizophrenia and bipolar disorder, on brain function in a sample of 102 ten- to twelve-year-old children. Each participant performed a Go/Nogo task, whereas brain responses were measured using functional magnetic resonance imaging. Statistical parametric mapping was used to estimate the impact of genetic variation in NRG1 on brain activation. Response accuracy and reaction times did not differ as a function of NRG1 genotype. However, individuals with the high-risk variant expressed greater brain activation for both Go and Nogo stimuli in the right posterior orbital gyrus, where NRG1 genotype accounted for 11% of interindividual variance. There were no regions showing a significant interaction between NRG1 genotype and stimulus type even at trend level, suggesting that the impact of NRG1 on brain activation was not specific to either response inhibition or motor execution. These results suggest that that genetic variation in NRG1 is associated with different levels of prefrontal engagement in children as young as 10-12 years of age. Our investigation provides support to the idea that genetic factors may affect brain function to moderate vulnerability to psychopathology from childhood. 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19449332      PMCID: PMC6870947          DOI: 10.1002/hbm.20818

Source DB:  PubMed          Journal:  Hum Brain Mapp        ISSN: 1065-9471            Impact factor:   5.038


  42 in total

1.  Error-related brain activation during a Go/NoGo response inhibition task.

Authors:  V Menon; N E Adleman; C D White; G H Glover; A L Reiss
Journal:  Hum Brain Mapp       Date:  2001-03       Impact factor: 5.038

2.  Comparing event-related and epoch analysis in blocked design fMRI.

Authors:  Andrea Mechelli; Rik N A Henson; Cathy J Price; Karl J Friston
Journal:  Neuroimage       Date:  2003-03       Impact factor: 6.556

Review 3.  Neuregulins: functions, forms, and signaling strategies.

Authors:  Douglas L Falls
Journal:  Exp Cell Res       Date:  2003-03-10       Impact factor: 3.905

Review 4.  Neurofunctional correlates of vulnerability to psychosis: a systematic review and meta-analysis.

Authors:  Paolo Fusar-Poli; Jorge Perez; Matthew Broome; Stefan Borgwardt; Anna Placentino; Eduardo Caverzasi; Mariachiara Cortesi; Pierangelo Veggiotti; Peirluigi Politi; Francesco Barale; Philip McGuire
Journal:  Neurosci Biobehav Rev       Date:  2007-01-12       Impact factor: 8.989

5.  Meta-analysis shows strong positive association of the neuregulin 1 (NRG1) gene with schizophrenia.

Authors:  Dawei Li; David A Collier; Lin He
Journal:  Hum Mol Genet       Date:  2006-05-10       Impact factor: 6.150

6.  Rostral and orbital prefrontal cortex dysfunction in the manic state of bipolar disorder.

Authors:  H P Blumberg; E Stern; S Ricketts; D Martinez; J de Asis; T White; J Epstein; N Isenberg; P A McBride; I Kemperman; S Emmerich; V Dhawan; D Eidelberg; J H Kocsis; D A Silbersweig
Journal:  Am J Psychiatry       Date:  1999-12       Impact factor: 18.112

7.  Individuals with schizophrenia present hypo- and hyperactivation during implicit cueing in an inhibitory task.

Authors:  Estibaliz Arce; David S Leland; Daniel A Miller; Alan N Simmons; Kelly C Winternheimer; Martin P Paulus
Journal:  Neuroimage       Date:  2006-08-15       Impact factor: 6.556

8.  Developmental increase in top-down and bottom-up processing in a phonological task: an effective connectivity, fMRI study.

Authors:  Tali Bitan; Jimmy Cheon; Dong Lu; Douglas D Burman; James R Booth
Journal:  J Cogn Neurosci       Date:  2009-06       Impact factor: 3.225

9.  Acquiring and inhibiting prepotent responses in schizophrenia: event-related brain potentials and functional magnetic resonance imaging.

Authors:  Judith M Ford; Max Gray; Susan L Whitfield; And U Turken; Gary Glover; William O Faustman; Daniel H Mathalon
Journal:  Arch Gen Psychiatry       Date:  2004-02

10.  Association of Neuregulin 1 with schizophrenia and bipolar disorder in a second cohort from the Scottish population.

Authors:  P A Thomson; A Christoforou; S W Morris; E Adie; B S Pickard; D J Porteous; W J Muir; D H R Blackwood; K L Evans
Journal:  Mol Psychiatry       Date:  2006-08-29       Impact factor: 15.992

View more
  4 in total

1.  Lack of association to a NRG1 missense polymorphism in schizophrenia or bipolar disorder in a Costa Rican population.

Authors:  Emily Moon; Brandi Rollins; Andrea Mesén; Adolfo Sequeira; Richard M Myers; Huda Akil; Stanley J Watson; Jack Barchas; Edward G Jones; Alan Schatzberg; William E Bunney; Lynn E DeLisi; William Byerley; Marquis P Vawter
Journal:  Schizophr Res       Date:  2011-07-13       Impact factor: 4.939

Review 2.  Neurocognitive-genetic and neuroimaging-genetic research paradigms in schizophrenia and bipolar disorder.

Authors:  Yoanna Arlina Kurnianingsih; Carissa Nadia Kuswanto; Roger S McIntyre; Anqi Qiu; Beng Choon Ho; Kang Sim
Journal:  J Neural Transm (Vienna)       Date:  2011-06-19       Impact factor: 3.575

Review 3.  Bad wrap: Myelin and myelin plasticity in health and disease.

Authors:  Erin M Gibson; Anna C Geraghty; Michelle Monje
Journal:  Dev Neurobiol       Date:  2017-10-17       Impact factor: 3.964

4.  Informing the Structure of Executive Function in Children: A Meta-Analysis of Functional Neuroimaging Data.

Authors:  Róisín McKenna; T Rushe; Kate A Woodcock
Journal:  Front Hum Neurosci       Date:  2017-04-07       Impact factor: 3.169

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.